GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

Search

Camurus AB

Fermé

604 2.11

Résumé

Variation du prix de l'action

24h

Actuel

Min

585

Max

606.5

Chiffres clés

By Trading Economics

Revenu

31M

197M

Ventes

5.2M

558M

P/E

Moyenne du Secteur

64.511

50.291

BPA

3.29

Marge bénéficiaire

35.328

Employés

265

EBITDA

21M

190M

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.2B

35B

Ouverture précédente

601.89

Clôture précédente

604

Camurus AB Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 juin 2025, 23:49 UTC

Résultats

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 juin 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 juin 2025, 21:30 UTC

Résultats

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Résultats

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 juin 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 juin 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 juin 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 juin 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 juin 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 juin 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 juin 2025, 23:19 UTC

Acquisitions, Fusions, Rachats

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 juin 2025, 22:06 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:15 UTC

Résultats

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 juin 2025, 21:07 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 juin 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 20:52 UTC

Résultats

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 juin 2025, 20:51 UTC

Résultats

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Camurus AB prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.